This notification has no immediate effect on the listing or trading of NeuroSense’s ordinary shares on the Nasdaq Capital Market CAMBRIDGE, Mass., Dec. 27, 2023 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense” or the “Company”), a company developing treatments for…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.